Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 4Pain, Postoperative 2Vomiting 1Urinary Incontinence, Stress 1Urinary Incontinence 1Urinary Bladder Neoplasms 1Shoulder Pain 1Psychomotor Agitation 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Ovarian Cysts 1Neuroblastoma 1Neoplasms 1Myofibroma 1Menstruation Disturbances 1Lung Neoplasms 1Liver Neoplasms 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1Gynecologic Oncology Patient 1Endometrial Neoplasms 1Cognitive Dysfunction 1Anxiety Disorders 1Advanced Breast Cancer 1

Interventions

Fulvestrant 5Anastrozole 4Letrozole 3Docetaxel 2Dasatinib 2vandetanib 1sonidegib 1ribociclib 1pembrolizumab 1palbociclib 1olaparib 1irinotecan sucrosofate 1exemestane 1cediranib 1XMT-1522 1Vorinostat 1Tablets 1Ritonavir 1Population Groups 1Paclitaxel 1Moxifloxacin 1Itraconazole 1Histone Deacetylase Inhibitors 1Gemcitabine 1FCN-437c 1Everolimus 1Electroporation 1Cryosurgery 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Breast Cancer × Population Groups × Clear all
NCT06290466 2024-03-04

Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects

Ahon Pharmaceutical Co., Ltd.

Phase 1 Completed
18 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡